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INTRODUCTION
Branch retinal vein occlusion (BRVO) is a common retinal vascular 
disorder that can lead to significant visual loss, particularly when se­
con dary macular edema (ME) develops(1).
Although laser photocoagulation has been the only effective evi­
dence­based treatment for such patients, recent evidence supports 
the use of intravitreal pharmacotherapies as valid adjuncts or even as 
alternative treatments to standard laser photocoagulation(2).
Once a BRVO develops, retinal ischemia ensues downstream from 
the site of occlusion. Retinal ischemia and hypoxia are the most im ­
por tant upregulators of vascular endothelial growth factor (VEGF) 
pro duction(3), which constitutes one of the most potent permeabili­
zin g agents known and which has been implicated in the pathoge­
nesis of ME of various etiologies(4,5). Therefore, VEGF inhibition appears 
to be a promising treatment modality for ME(6). In fact, recent studies 
have suggested a beneficial effect of intravitreous anti­VEGF agents 
such as bevacizumab for the reduction of ME from different etiolo­
gies, including BRVO(7­10). Some authors reported improvement in 
best corrected visual acuity (BCVA) at 1, 4, 8, and 12 weeks after just 
one intravitreal bevacizumab (IVB) injection; however, no significant 
improvement was noted after 24 weeks(11). In 2007, a study reported 
that ME accompanied by BRVO recurred 2.1 months after injection 
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ABSTRACT
Purpose: To evaluate the effect of a single intravitreal bevacizumab injection on visual 
acuity, contrast sensitivity and optical coherence tomography­mea su red cen tral 
macular thickness in eyes with macular edema from branch re tinal vein occlusion. 
Methods: Seventeen eyes of 17 patients with macular edema from unilateral branch 
retinal vein occlusion were treated with a single bevacizumab injection. Patients were 
submitted to a complete evaluation including best corrected visual acuity, contrast 
sensitivity and optical coherence tomography measurements before treatment and 
one and three months after injection. Visual acuity, contrast sensitivity and optical 
coherence tomography measurements were compared to baseline values. 
Results: Mean visual acuity measurement improved from 0.77 logMAR at baseli­
ne to 0.613 logMAR one month after injection (P=0.0001) but worsened to 0.75 
logMAR after three months. Contrast sensitivity test demonstrated significant 
improvement at spatial frequencies of 3, 6, 12 and 18 cycles/degree one month 
after injection and at the spatial frequency of 12 cycles/degree three months after 
treatment. Mean ± standard deviation baseline central macular thickness (552 
± 150 µm) reduced sig ni ficantly one month (322 ± 127 µm, P=0.0001) and three 
mo nths (439 ± 179 µm, P=0.01) after treatment. 
Conclusions: Bevacizumab injection improves visual acuity and contrast sensitiv i t y 
and reduces central macular thickness one month after treatment. Visual acuity returns 
to baseline levels at the 3­month follow­up, but some beneficial effect of the treatment 
is still present at that time, as evidenced by optical coherence tomography­mea sured 
central macular thickness and contrast sensitivity measurements.
Keywords: Macular edema; Retinal vein occlusion; Contrast sensitivity; Optical cohe­
rence tomography; Vascular endothelial growth factor A; Angiogenesis inhibitors/
the rapeutic use; Antibodies monoclonal; Visual acuity; Injections
RESUMO 
Objetivo: Avaliar o efeito de uma única injeção intravítrea de bevacizumabe na fun ção 
visual, sensibilidade ao contraste, em olhos com edema macular causado por oclusão de 
ramo venoso retiniano. 
Métodos: Dezessete olhos de 17 pacientes com edema macular unilateral causado por 
oclu são de ramo venoso retiniano foram tratados com uma única injeção intraví trea 
de bevacizumabe. Pacientes previamente foram submetidos a exame ocular com pleto, 
sensibilidade ao contraste, variável de maior interesse, melhor acuidade visual corrigida 
e tomografia de coerência óptica e foram reavaliados no 1o e 3o mês de seguimento. 
Resultados: O teste de sensibilidade ao contraste demonstrou melhora significan te nas 
frequências espaciais 3, 6, 12 e 18 ciclos/grau (c/g) no primeiro mês de segui men to e 
na frequência espacial 12 c/g após o 3o mês de tratamento. A média da acuidade visual 
melhorou de  0,77 no pré-tratamento para 0,61 logMAR no 1o mês de seguimento (P=0,0001), 
com piora ao final do 3o mês, 0,75 logMAR. A média da espessura foveal central (552 ± 150 
µm) reduziu significantemente no 1o (322 ± 127 µm, P=0,0001) e 3o (439 ± 179 µm, P=0,01) 
mês de seguimento. 
Conclusão: No edema macular causado por oclusão de ramo venoso retiniano, uma 
única injeção intravítrea de bevacizumabe melhora a sensibilidade ao contraste, acui-
dade visual e reduz a espessura foveal central após 1 mês de tratamento. Após 3 meses de 
seguimento, ainda é possível observar benefício com o tratamento, como foi evi denciado 
pela sen sibilidade ao contraste e a medida da espessura foveal central à tomografia de 
coerência óptica.
Descritores: Edema Macular; Oclusão da veia retiniana; Sensibilidade de contraste; 
Tomografia de coerência óptica; Fator A de crescimento do endotélio vascular; Inibidores 
da angiogênese/uso terapêutico; Anticorpos monoclonais; Acuidade visual; Injeções
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intravitreal bevacizumab (IVB) injection(12), while others reported that 
the effects disappeared after 6 weeks(2,10). In other study, eyes were 
treated with three initial IVB injections of 1.25 mg at monthly in­
ter vals. Subsequent retreatment was based on optical coherence 
tomography (OCT)­measured central retinal thickness(13).
Most of the previous studies evaluating IVB injection in eyes with 
BRVO have based their conclusions on BCVA and central macular 
thi ckness (CMT) measurements on OCT. However, it is important to 
con sider that the use of other vision­function tests may provide va ­
lua ble additional information in order to further evaluate the effects of 
treat ment(14­17). Contrast sensitivity (CS) is one such test that provides 
a measure of the ability to see low­contrast patterns, and it has been 
suggested that it can provide more information on visual function than 
BCVA(14,18). The strong associations between CS and functional abilities 
provide a rationale for including CS measurements in clinical trials(19).
It seems clear from the above­mentioned studies that recurren ­
ce of ME after initial successful treatment is very common, and 
many authors have suggested two to three injections over the first 
5­6 months after vein occlusion(12,20). Other authors advise repeating 
IVB injection every time ME is present(21), with frequencies of up to 
one injection every 6 weeks(22) at an increased risk of complications. 
Therefore, des pite the general belief that repeated IVB injections are 
needed for the treatment of ME from BRVO, there are several issues 
open to ques tioning regarding the use of IVB injection. The most 
important issue is that the exact duration of the effect of IVB injec­
tion in eyes with ME from BRVO is not clear, and therefore clear­cut 
recommendations as to the frequency of IVB use are not available. 
Although patients may be given multiple injections, it is important 
to know what to ex pect of the first treatment ­ an issue that has not 
been properly dealt with in previous studies ­ in order to reasonably 
support a certain therapeutic regimen. The purpose of the present 
study is therefore to evaluate prospectively the effect of a single IVB 
injection on OCT­estimated ME, BCVA and CS in patients with BRVO 
followed for 3 months.
METHODS
This was an interventional, prospective, consecutive study con duc­
ted between October 2008 and December 2009. The study followed 
the principles of the Declaration of Helsinki, approval from the Insti ­
tutional Review Board Ethics Committee was obtained and all parti­
cipants gave their informed consent.
The study included 17 eyes of 17 patients (10 women) with a diag ­
nosis of ME due to unilateral BRVO confirmed by OCT, fluorescein 
an giography and fundus photography. Patients were included in the 
study independent of the size of the area of leakage and time of 
occur rence of BRVO. Other inclusion criteria were CMT, as determined 
by OCT, greater than 300 µm, best­corrected distance VA measure­
ment worse than 20/40 and absence of previous treatment over the 
last 3 months.
BCVA measurements were performed with the Early Treatment 
Diabetic Retinopathy Study (ETDRS) chart (Precision Vision, Aurora, Colo­
rado, USA). Contrast sensitivity was measured with the VCTS® 6500 
(Vistech Consultants Incorporation, Dayton, OH, USA) in photopic 
con ditions (85 cd/m2) that allows evaluation of 5 spatial frequen cies 
with sinewave grating charts ranging between 1.5 and 18 cycles/
degree (cpd). The patient should view the chart monocularly from 
a 10­foot distance (or 3­foot distance for low vision) with the best 
specta cle correction in place. The test proceeded from higher to 
lower contrast and from lower to higher spatial frequency. At each 
spatial fre quency, the target with the lowest contrast that was cor­
rectly iden tified before any preceding error was recorded as the CS 
for that frequency. The contrast threshold was measured from the 
last correct response. CS values, derived from the table provided 
in the Vistech manual, ranged from 3 to 260 and depended on the 
frequency. The CS levels in each row ranged from 0.47 to 2.23; 0.60 to 
2.34; 0.70 to 2.41; 0.70 to 2.23; and 0.60 to 1.95 log units for 1.5, 3, 6, 
12, and 18 cycles/degree, respectively.
Patients received one single intravitreal injection (1.25 µg/0.05 cc) of 
bevacizumab. VA, CS, fluorescein angiography and OCT were perfor­
med immediately prior to treatment and repeated at 1 and 3 months 
after injection. All injections were performed following international 
guidelines at operating room sterile drape, previous 5% topical po­
vidone(23), and prophylactic topical antibiotics were given for 2 days 
before and 3 days postinjection.
Fluorescein angiograms were obtained after injection of 5 mL of 
10% sodium fluorescein solution into the antecubital vein. The time 
for the dye to first appear in the arterioles until the end of the lami­
nar filling stage was recorded as the arterial venous filling time. The 
classification of BRVO was based on fluorescein angiographic criteria: 
ischemic lesions had 5 or more optic disc size areas of retinal non­per­
fusion while non­ischemic occlusions had less than 5 such lesions. 
Subjects underwent ocular imaging with dilated pupils using a 
commercially available, Stratus OCT (Carl Zeiss Meditec, Dublin, Cali­
fornia, USA). Quality assessment of Stratus OCT scans was evaluated 
by an experienced examiner. Good­quality scans had to have focused 
images and signal strength equal to or higher than 7 and radial scans 
centered on the fovea. The fast macular thickness protocol was used 
to obtain macular thickness measurements with the Stratus OCT. 
OCT measurements of the macula were generated from six 6 mm li­
near scans in a spokelike radial configuration with each line 30º apart. 
Macular thickness parameters were automatically calculated by the 
software (version 4.0.1) as the distance between the inner limiting 
membrane and retinal pigment epithelium.
Data regarding VA and CS were converted to logMAR before analy­
sis and calculations. The descriptive statistics included fre quen cy and 
mean value ± standard deviation (SD) for normally distri bu ted varia­
bles and median, first quartile and third quartile for non­normally 
distributed variables. Analysis of histograms and the Kolmogorov­
Smir nov test were used to evaluate the normality assumption. We 
used the paired t­test for comparisons of normally distributed para­
meters and the Wilcoxon signed­rank test for parameters that did not 
satisfy the normality assumption.
We calculated correlations using either Spearman’s rank or Pear­
son’s correlation coefficients. A P value of less than 0.05 was consi­
dered statistically significant. The statistical analyses were performed 
using the software SPSS v.15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 17 intravitreal injections of bevacizumab were perfor­
med with no ocular or systemic adverse reactions noted. Seventeen 
patients completed the 1­month follow­up period, and 13 patients 
com pleted the 3­month follow­up period.
At baseline, none of the eyes had evidence of retinal or iris neo­
vascularization or elevated intraocular pressure. The mean age ± SD 
was 65.5 ± 12.1 years. The mean duration of symptoms ± SD before 
treatment was 29.0 ± 28.6 weeks (range 2­96 weeks). The majority 
of the cases presented the temporal inferior branch being the site 
of occlu sion in, 9 (53%) of the eyes. This data differed from the study 
alrea dy published(24) in which the majority of patients presented the 
superior branch as the main occlusion site.
The mean baseline VA of 17 affected eyes was 0.772 logMAR. After 
injection, 17 eyes had a 1­month follow­up visit, which demonstrated 
an improvement in the mean VA to logMAR 0.613, (P=0.0001). Thir­
teen eyes had a 3­month follow­up visit; the mean baseline VA was 
0.75 logMAR and after 3 months of follow­up, 0.77 logMAR (P=0.139), 
demonstrating no statistical significance (Figure 1).
The CS test demonstrated in photopic conditions statistical 
sig ni fi cance in all spatial frequencies of 1.5 (P=0.10), 3 (P=0.005), 
6 (P=0.003), 12 (P=0.001) and 18 cycles/degree (P=0.007) at 4­week 
follow­up. Statistical significance was observed after 3 months of treat ­
ment in the high spatial frequency of 12 cycles/degree (P=0.034), 
between the thirteen eyes (Table 1). 
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When considering the time of BRVO, patients’ results which had 
a disease history of less than 1 year, 8 (0.47%), was 1.5 (P=0.186), 3 
(P=0.047), 6 (P=0.048), 12 (P=0.021) and 18 cycles/degree (P=0.031). 
And patients with a history of more than 1 year, 9 (0.53%): 1.5(P=0.012), 
3 (P=0.051), 6 (P=0.023), 12 (P=0.001) and 18 cycles/degree (P=0.052). 
Those patients who completed 3 months of follow­up with less than 
1 year of disease, 8 (61.5%), exhibited 1.5 (P=0.221), 3 (P=0.805), 6 
(P=0.762), 12 (P=0.174) and 18 cycles/degree (P=0.327), and patients 
of more than1 year, 5 (38.5%), 1.5 (P=0.425), 3 (P=0.881), 6 (P=0.101), 
12 (P=0.070) and 18 cycles/degree (P=0.584).
Statistically significant reductions in CMT by OCT were demons­
trated after a single bevacizumab injection at the 4­week visit. Seven­
teen eyes had a 4­week follow­up OCT; the mean CRT was 552.47 
± 150.36 µm at initial presentation and 322 ± 127 µm at the 4­week 
visit (P=0.0001). Among the thirteen eyes at the 3­month follow­up, 
the mean CMT was 570.77 ± 159.3 µm at initial presentation and 439 
± 179 µm at the 3­month visit (P=0.01) (Figure 2).
A statistically significant negative correlation was observed at the 
3­month follow­up between CMT measurements and CS at spatial 
frequencies of 1.5 (P=0.14), 3 (P=0.002), 6 (P=0.001), and 12 (P=0.002) 
cpd (Spearman’s rank correlation test). A statistically significant posi­
tive correlation was observed between CMT measurements and 
best­cor rected VA measured at 1­month (P=0.022) and 3­month 
(P=0.025) follow­up (Pearson’s correlation test).
DISCUSSION
Several studies support the hypothesis that VEGF inhibition has 
a beneficial effect in eyes with ME secondary to BRVO, at least in the 
short term(8,10­12,20­22). Two small prospective case series(8,12) showed sig­
nificant improvement in VA and OCT­measured CMT one month after 
a single IVB injection. Our data also confirm such findings because a 
highly statistically significant improvement was observed, in VA and 
OCT­measured CMT. 
Nevertheless, the snellen VA test is a relatively crude index of vi­
sual function, until now it measures resolution only with high contrast 
targets, whereas objects in the real world exhibit varying degrees of 
contrast and a varying content of spatial frequencies(25). This study 
measured CS and found improvement in 17 patients with ME from 
BRVO after a single IVB injection, between one and three months of 
follow up. 
Considering middle (6 cycles/degree) and both high spatial fre­
quen cies (12 and 18 cycles/degree), patients with a history of less 
than 1 year demonstrated improvement in the middle and both high 
spatial frequencies when compared to patients with a history of more 
than 1 year that demonstrated improvement in the middle spatial fre­
quencies and among the highs, in the 12 and 18 cycles/degrees, only 
in the 12th cycle/degree. Nevertheless, in the 3 months of follow­up, 
no statistical significance was found. This could be perhaps due to the 
small number of patients or due time of reporting the disease by the 
patient does not match with the true onset time of BRVO, since the 
majority of the patients with the disease could be asymptomatic(26).
In our study, the dose of 1.25 mg of bevacizumab was similar to 
several previous studies(8,10­13,21,22) using the same treatment modality 
ex cept for that used in the study published in 2007 which used 2.5 mg 
of bevacizumab with similar favorable results(20). The favorable effect 
of treatment observed in our study is also in agreement with the po ­
sitive results obtained by others authors which used repeated 2.0 mg 
bevacizumab injections at three months interval in patients with 
central and hemicentral retinal vein occlusion(27).
While it seems clear that IVB injection has a short­term beneficial 
effect, it is also clear from several studies that recurrence of ME is 
rather frequent(8,11,12), and very often repeated injections are neces­
sary in patients with retinal vein occlusion. The exact duration of the 
beneficial effect of a single IVB injection is still unknown, and very 
few studies have addressed this issue in a systematic way in patients 
with BRVO.
Studies evaluated retrospectively the effect of IVB injection in 
eyes with ME from BRVO. While in all studies reduction of ME was clear 
after a few weeks, multiple repeated injections were used in three of 
these studies(10,12,21), making it difficult to evaluate the exact duration 
Figure 1. Box plot chart showing best corrected visual acuity before, 1 month and 
3 months after intravitreal Bevacizumab injection in eyes with macular edema from 
branch retinal vein occlusion.
Table 1. Comparison of contrast sensitivity between baseline, 1 month 
and 3 months after intravitreal injection of bevacizumab in eyes with 
macular edema from branch retinal vein occlusion
Spatial frequency 
(cycles/degree)
1.5  
(Low)
3  
(Low)
6  
(Middle)
12  
(High)
18  
(High)
Baseline 0.93 1.20 0.98 0.52 0.46
1 month 1.13* 1.46* 1.37* 1.04* 0.72*
3 months 0.87 1.16 1.06 0.80* 0.35
*= P<0.05 Wilcoxon test
Figure 2. Central macular thickness before, 1 month and 3 months after intravitreal 
be vacizumab injection in eyes with macular edema from branch retinal vein occlusion.
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of the first treatment. On the other hand, the effect of a single IVB 
injection was evaluated retrospectively in 22 eyes with ME from BRVO 
and compared the effect of triamcinolone acetonide injection in 28 
eyes. BCVA improved at 1, 4, 8 and 12 weeks but not at 24 weeks 
postinjection in the bevacizumab group(11).
Three prospective studies evaluated the role of bevacizumab 
injection after BRVO. The first evaluated 22 patients with BRVO who 
received 2.5 mg of IVB injection. The injections were repeated every 
6 weeks when persistent or recurring ME was noted(20). The second 
evaluated 12 patients with BRVO who received a single 1.25 mg beva­
cizumab injection and were followed for 3 months. Visual acuity and 
OCT­measured CMT improved at 1 and 3 months after treatment(8). 
The third evaluated the response of a single bevacizumab treatment 
in 7 eyes with BRVO. Improvement in VA reached a peak between 
3 and 6 weeks after injection, while a decrease in VA was observed 
between weeks 6 and 9. The authors suggest that using OCT exami na­
tion between weeks 3 and 6 after the first treatment may be helpful in 
judging the appropriate time for reinjection(28). The need of multiple 
repeat anti­VEGF injections has also been recently emphasized by 
the Branch Retinal Vein Occlusion (BRAVO) study where patients were 
evaluated with monthly injections of Ranibizumab for 6 months. The 
study enrolled 397 patients and demonstrated great beneficial in 
central macular thickness measurements in the treated group over 
a sham group(29). 
Our study is important because we have evaluated in a systema­
tic way the effect of a single IVB injection after one and three months, 
using not only VA and OCT­measured CMT, but also careful CS func­
tion. The reason for the continuance of CS improvement after three 
months of follow­up even the VA did not demonstrate it could be 
be cause some eyes with reduced central vision may surprisingly 
show good contrast sensitivity, especially for gratings of low spatial 
frequencies(25). 
CS is more closely associated with tasks requiring distance judg­
ment, night driving and mobility(15). Patients with limitations in distin­
guishing contrast could have difficulties in several day­to­day situa­
tions(14). Because it is already known that the ability of an individual 
to realize the details of an object is determined mainly by how that 
person distinguishes contrast(30), evaluating CS is extremely impor­
tant when assessing the effect of new treatment modalities. Because 
of this, considering both VA and CS when assessing the outcomes of 
clinical trials may provide a more complete picture of the effects of 
treatment on vision than either measure alone(19). Our study indicated 
that a single IVB injection produces significant improvement in VA, CS 
and macular thickness measurements 4 weeks after injection, and the 
improvements regarding CS and macular thickness measurements 
last for at least 12 weeks, although VA did not differ when compared 
to preoperative evaluation. The optimum dosing and sequence for 
IVB injection in BRVO is still undetermined. While the exact number 
of injections necessary to maintain improved VA in cases of BRVO is 
unknown, our study indicates that improvement in CS and CMT is still 
present 3 months after a single IVB injection.
We acknowledge some shortcomings of our study, which include 
a relatively small number of patients, a lack of controls and a short 
follow­up. Nevertheless, clear evidence could be obtained that IVB in­
jection rapidly improved VA, CS and CMT in the short­term follow­up, 
and the beneficial effects persisted after 3 months for CMT and CS. 
Multicenter clinical trials are necessary to prove the long­term effect 
of bevacizumab, as well as to determine the frequency of repeated 
injections for the treatment of ME due to BRVO.
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